IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0070498
(1993-06-02)
|
발명자
/ 주소 |
- Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO)
|
출원인 / 주소 |
- Atrix Laboratories, Inc. (Fort Collins CO 02)
|
인용정보 |
피인용 횟수 :
243 인용 특허 :
24 |
초록
▼
The invention is directed to an improved system for controlled release of biologically active materials and to a liquid composition for its formation. The liquid composition is composed of a thermoplastic polymer, rate modifying agent, bioactive material and organic solvent. The liquid composition i
The invention is directed to an improved system for controlled release of biologically active materials and to a liquid composition for its formation. The liquid composition is composed of a thermoplastic polymer, rate modifying agent, bioactive material and organic solvent. The liquid composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of biologically active substances to tissues or organs.
대표청구항
▼
A thermoplastic polymer system suitable as a controlled release implant, comprising: a solid, microporous matrix of a pharmaceutically acceptable, biodegradable thermoplastic polymer which is insoluble in aqueous medium or human or animal body fluids, a biologically active agent, and up to about 15%
A thermoplastic polymer system suitable as a controlled release implant, comprising: a solid, microporous matrix of a pharmaceutically acceptable, biodegradable thermoplastic polymer which is insoluble in aqueous medium or human or animal body fluids, a biologically active agent, and up to about 15% by weight of a pharmaceutically acceptable, water-insoluble, rate-retarding agent which retards the rate of release of the biologically active agent from the matrix up to 100 fold relative to its rate of release from the same matrix without the rate-retarding agent, and which imparts a Tg to the matrix of less than about 55°C., the weight being relative to the total weight of the matrix; and, the microporous matrix being formed externally or in situ respectively by a process comprising combining a composition with the aqueous medium, or administering the composition directly into a body tissue or cavity having the human or animal body fluids; the composition comprising the thermoplastic polymer, the biologically active agent, the rate-retarding agent and a pharmaceutically acceptable organic solvent in which the thermoplastic polymer, biologically active agent and rate-retarding agent are dissolved or dispersed, the organic solvent being miscible to dispersible in aqueous medium or human or animal body fluids; the combining step or administering step resulting in diffusion of the organic solvent into the aqueous medium or body fluid and resulting in coagulation of the thermoplastic polymer to form the solid microporous matrix; the thermoplastic polymer being selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyothoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), and copolymers, terpolymers and any combination thereof, and the thermoplastic polymer having a molecular weight up to about 0.8 inherent viscosity; and, the rate-retarding agent being selected from the group consisting of an ester of a mono, di or tricarboxylic acid, a polyhydroxy alcohol, a fatty acid, a fatty acid ester, an epoxidized oil, a sterol, a higher alkyl alcohol, and any mixture thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.